Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | CALCR | P30988 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272450 | 0.92 | F2 (0.46) | F2MC4RF2ROPRK1CALCR | |
| SCHEMBL30827585 | 0.91 | MC4R (0.46) | F2MC4RF2ROPRK1STAT3 | |
| SCHEMBL29590547 | 0.90 | OPRK1 (0.46) | MC4RF2ROPRK1STAT3 | |
| SCHEMBL29630560 | 0.90 | OPRK1 (0.46) | MC4RF2ROPRK1STAT3 | |
| SCHEMBL29555036 | 0.89 | ACE (0.41) | F2MC4RF2RAPLNROPRK1 | |
| SCHEMBL30165153 | 0.89 | MC4R (0.47) | F2MC4RF2RAPLNROPRK1 | |
| SCHEMBL30827588 | 0.88 | MC4R (0.47) | F2MC4RF2RCALCR | |
| SCHEMBL29630596 | 0.87 | MEN1 (0.43) | MC4ROPRK1STAT3 | |
| SCHEMBL30454445 | 0.87 | CAPN1 (0.46) | F2APLNROPRK1 | |
| SCHEMBL29592647 | 0.86 | MC4R (0.41) | F2MC4RAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2026-05-07 | — | — | US | claimed |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2024-03-14 | — | — | US | claimed |
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4218815-A2 | USE OF ANTI IL-1BETA ANTIBODIES | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-4177268-A2 | NEW INDICATIONS FOR ANTI-IL-1BETA THERAPY | Novartis AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| EP-3332807-B1 | USE OF ANTI IL-1BETA ANTIBODIES | NOVARTIS AG (CH) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | IL1A, IL1R1, FCGR2A | F2 4175/4885MC4R 2746/4885F2R 724/4885 |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | IL1B, IL1RN, IL1A | F2 3942/4885MC4R 1681/4885F2R 619/4885 |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | IL1RN, IL1A, IL1B | F2 2980/4885MC4R 1524/4885F2R 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.